Clinical Trial Update: Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a completed Phase 1/2 dose-finding and safety study of ibrutinib in pediatric patients with chronic graft-versus-host disease (cGVHD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Chronic Graft Versus Host Disease | Phase 1, Phase 2 | Status: COMPLETED